Clinical Trial Results: Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in combination with liver-directed therapy or peptide receptor radionuclide therapy for neuroendocrine tumors with liver …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Metastases
• Neuroendocrine Neoplasm

Drugs mentioned

• Liver-directed therapy
• Pembrolizumab (pembrolizumab)
• Peptide Receptor Radionuclide Therapy

Snippet

Sponsor: Nicholas Fidelman, MD | Conditions: Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2026-08-28